Neoantigen-specific CD4(+) T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy by Peng, Peng et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Articles, Abstracts, and Reports 
9-1-2020 
Neoantigen-specific CD4(+) T-cell response is critical for the 
therapeutic efficacy of cryo-thermal therapy 
Peng Peng 
Hong-Ming Hu 
Laboratory of Cancer Immunobiology, Earle A. Chiles Research Institute, Providence Portland Medical 
Center, Portland, OR, USA. 
Ping Liu 
Lisa X Xu 
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications 
 Part of the Immunotherapy Commons, and the Oncology Commons 
Recommended Citation 
Peng, Peng; Hu, Hong-Ming; Liu, Ping; and Xu, Lisa X, "Neoantigen-specific CD4(+) T-cell response is 
critical for the therapeutic efficacy of cryo-thermal therapy" (2020). Articles, Abstracts, and Reports. 3621. 
https://digitalcommons.psjhealth.org/publications/3621 
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has 
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. 
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org. 
1Peng P, et al. J Immunother Cancer 2020;8:e000421. doi:10.1136/jitc-2019-000421
Open access 
Neoantigen-­specific­CD4+ T- cell 
response is critical for the therapeutic 
efficacy­of­cryo-­thermal­therapy
Peng Peng   ,1 Hongming Hu,2 Ping Liu,1 Lisa X Xu1
To cite: Peng P, Hu H, Liu P, 
et al.  Neoantigen- specific 
CD4+ T- cell response is critical 
for the therapeutic efficacy of 
cryo- thermal therapy. Journal 
for ImmunoTherapy of Cancer 
2020;8:e000421. doi:10.1136/
jitc-2019-000421
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ jitc- 
2019- 000421).
Accepted 23 August 2020
1School of Biomedical 
Engineering, Shanghai Jiao Tong 
University, Shanghai, China
2Providence Portland Medical 
Center, Earle A Chiles Research 
Institute, Portland, Oregon, USA
Correspondence to
Professor Ping Liu;  
 pingliu@ sjtu. edu. cn
Original research
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Background Traditional tumor thermal ablations, such as 
radiofrequency ablation (RFA) and cryoablation, can result 
in good local control of tumor, but traditional tumor thermal 
ablations are limited by poor long- term survival due to 
the failure of control of distal metastasis. Our previous 
studies developed a novel cryo- thermal therapy to treat 
the B16F10 melanoma mouse model. Long- term survival 
and T- cell- mediated durable antitumor immunity were 
achieved after cryo- thermal therapy, but whether tumor 
antigen- specific T- cells were augmented by cryo- thermal 
therapy was not determined.
Methods The long- term antitumor therapeutic efficacy 
of cryo- thermal therapy was performed in B16F10 murine 
melanoma models. Splenocytes derived from mice treated 
with RFA or cryo- thermal therapy were coincubated 
with tumor antigen peptides to detect the frequency of 
antigen specific CD4+ and CD8+ T- cells by flow cytometry. 
Splenocytes were then stimulated and expanded by αCD3 
or peptides and adoptive T- cell therapy experiments were 
performed to identify the antitumor efficacy of T- cells 
induced by RFA and cryo- thermal therapy. Naïve mice and 
tumor- bearing mice were used as control groups.
Results Local cryo- thermal therapy generated a stronger 
systematic antitumor immune response than RFA and a 
long- lasting antitumor immunity that protected against 
tumor rechallenge. In vitro studies showed that the 
antigen- specific CD8+ T- cell response was induced by both 
cryo- thermal therapy and RFA, but the strong neoantigen- 
specific CD4+ T- cell response was only induced by cryo- 
thermal therapy. Cryo- thermal therapy- induced strong 
antitumor immune response was mainly mediated by CD4+ 
T- cells, particularly neoantigen- specific CD4+ T- cells.
Conclusion Cryo- thermal therapy induced a stronger 
and broader antigen- specific memory T- cells. Specifically, 
cryo- thermal therapy, but not RFA, led to a strong 
neoantigen- specific CD4+ T- cell response that mediated 
the resistance to tumor challenge.
BACKGROUND
It is increasingly acknowledged that the 
induction of long- lasting antitumor immunity 
is critical in cancer treatment.1 Modulating 
the immune system to enhance the antitumor 
response has improved cancer survival.2 
Immunotherapy is a powerful, developing 
cancer treatment modality that can be 
combined with chemotherapy, radiotherapy 
and other traditional treatments from preclin-
ical development to clinical application.3 
However, immunotherapy is still limited by 
the low rate of response, unpredictable effi-
cacy and off- target side effects.4
With the development of modern imaging, 
local thermal ablation is increasingly used for 
clinical cancer treatment. Radiofrequency 
ablation (RFA) and cryoablation are two 
main energy- based approaches. In the central 
zone of RFA, where the temperature can be 
increased by more than 60℃, the tumor cells 
undergo coagulative necrosis.5 6 Neutrophils, 
macrophages, dendritic cells (DCs), natural 
killer cells (NK cells), B cells and T- cells 
infiltrate into the transitional zone, where 
tumor cells are either undergoing apoptosis 
or recovering from reversible injury after 
RFA.7 Immunogenic intracellular substrates, 
including antigens and danger signals, are 
also released to activate innate immunity.8 
However, coagulative necrosis induced by RFA 
increases the tissue impedance and therefore 
limits further electrical conduction through 
the remaining tissue.9 As a result, intracel-
lular substrates from apoptotic tumor cells 
are not fully released, which may decrease 
the extent of the immunological response 
and even induce immunosuppression.10 In 
cryoablation, the lethal temperature of tumor 
cells is considered to be between −40℃ and 
−20℃.11 Although an antitumor immuno-
logical response is induced in cryoablation, 
such as production of tumor antigen- specific 
antibodies and T- cell and NK cell activation, 
the immunosuppressive effect of cryoablation 
limits its clinical therapeutic effect.11 12
To avoid the disadvantages of RFA and 
cryoablation, we combined these two thera-
pies to develop a novel tumor cryo- thermal 
therapy through the alternative cooling and 
heating of tumor tissue in preclinical animal 
models.13 14 The long- term survival rate 
was significantly improved in 4T1 murine 
mammary cancer and B16F10 murine 
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melanoma models.15–17 The acute proinflammatory cyto-
kines and danger signals released after cryo- thermal 
therapy efficiently activated innate immunity.15 16 18 19 
As a result, a long- lasting CD4+ T- cells- dependent anti-
tumor immune memory response was triggered.15 17 19 
However, whether tumor antigen- specific T- cells, espe-
cially neoantigen- specific T- cells, can be induced by cryo- 
thermal therapy has still not been investigated.
Neoantigens have been proven to be high immuno-
genic and used as potent tumor vaccines for melanoma 
patients.20 21 Accumulating evidence implies that the 
tumor regression initiated by immunotherapy is achieved 
via the activation of cytotoxic T- cells targeting neoanti-
gens.22 Some studies show that DNA mutation- derived 
peptides are more frequently used to induce neoantigen- 
specific CD4+ T- cells than CD8+ T- cells.20 23–25 Endogenous 
CD4+ T- cells recognizing neoantigens have been found in 
patients with cancer.26 27 Neoantigen- specific CD4+ T- cell 
responses can mediate the regression of metastatic epithe-
lial cancer.28 CD4+ T- cell neoepitopes- based vaccination 
in tumor- bearing mice resulted in rejection of established 
B16F10 melanoma and CT26 colon tumor models.21
In this study, we examined the tumor antigen- specific 
T- cells induced by cryo- thermal therapy in a B16F10 
murine melanoma model and investigated the role of 
tumor antigen- specific T- cells in cryo- thermal therapy- 
induced strong antitumor immunity. We found that 
cryo- thermal therapy induced a stronger systematic and 
long- term antitumor immunity compared with RFA. Both 
cryo- thermal therapy and RFA could induce tumor antigen- 
specific CD8+ T- cells; however, neoantigen- specific CD4+ 
T- cells were more efficiently induced after cryo- thermal 
therapy compared with RFA. Most importantly, we docu-
mented that neoantigen- specific CD4+ T- cells played an 
indispensable role in cryo- thermal therapy- induced long- 
term antitumor immunity. Thus, this study identified and 
elucidated the underlining mechanisms through which 
the local cryo- thermal therapy to induce neoantigen 




B16F10 mouse melanoma tumor cell line was donated 
by Weihai Yin at Med- X Research Institute, Shanghai 
Jiao Tong University. CT26 colon carcinoma cell line 
was donated by Yan Zhang at Med- X Research Institute, 
Shanghai Jiao Tong University. B16F10 cells were cultured 
in Dulbecco’s Modified Eagle’s Medium (GE Healthcare, 
Logan, Utah, USA) supplemented with 10% fetal bovine 
serum (FBS, Gemini Bio- Products, West Sacramento, 
California, USA), 100 units/mL penicillin and 100 µg/
mL streptomycin at 37°C in a humidified 5% CO2 incu-
bator. CT26 cells were cultured in Roswell Park Memorial 
Institute (RPMI)-1640 medium (Gibco, California, USA) 
supplemented with 10% FBS (Gemini Bio- Products), 100 
units/mL penicillin and 100 µg/mL streptomycin at 37°C 
in a humidified 5% CO2 incubator.
Animal models
The female C57BL/6 and BALB/c mice were obtained 
from the Shanghai Slaccas Experimental Animal (China) 
and used for experimental study at the age of 6–8 weeks. 
Mice were housed in isolated cages and a 12- hour light/
dark cycle environment, feeding with sterile food and 
acidified water with pH value kept at 7.5–7.8. To prepare 
the tumor- bearing mice, approximately 5×105 cells were 
injected subcutaneously into the right flank of each 
mouse. To investigate the distal effect of the treatment, 
approximately 1×105 B16F10 cells were injected subcuta-
neously on the left flank 7 days after primary injection.
The cryo-thermal therapy and RFA procedures
The system developed in our laboratory was composed 
of liquid nitrogen for cooling and RF for heating. To 
reduce the effect of contact thermal resistance and obtain 
a continuous thermal delivery during the treatment, a 
probe was designed with a cylinder- shaped tip of 1 mm in 
diameter for the thermal therapy of subcutaneous tumor. 
Subcutaneous injection of B16F10 melanoma cells into 
C57BL/6 mice leads to form primary tumors in 7–9 days 
and spontaneous metastasis in lungs. Twelve days after 
tumor inoculation, when the tumor volume reached 
about 0.2 cm3, the mice were divided into three groups: 
tumor- bearing group without the treatment (control), 
the cryo- thermal group with freezing at the tempera-
ture of −20°C for 5 min, followed by RF heating at the 
temperature of 50℃ for 10 min on primary tumor and 
the RFA group with RF heating at the temperature of 
60℃ for 15 min. The mice were anesthetized with intra-
peritoneal injection (i.p.) of 1.6% pentobarbital sodium 
(0.5 mL/100 g, Sigma- Aldrich, St. Louis, Missouri, USA). 
The tumor site was sanitized with 75% alcohol before the 
treatment. All the procedures were performed aseptically.
Tumor rechallenge analysis
Study of rechallenge with the B16F10 melanoma tumor 
cells was performed in survivors 45 days after treatment. 
Mice were intravenously infused with 1×105 B16F10 mela-
noma cells, and lung tumor nodules were enumerated 21 
days later.
Synthetic Peptides
gp10025-33 (EGSRNQDWL) (Purity: % peak area by 
HPLC ≥95%, purchased from ANASPEC), TYR368–376(YM-
DGTMSQV) (Purity: % peak area by HPLC ≥95%, 
purchased from ANASPEC), TRP2180-188 (SVYDFFVWL) 
(Purity: % peak area by HPLC ≥95%, purchased from 
ANASPEC), AH16-14(SPSYVYHQF) (Purity: % peak area 
by HPLC ≥95%, purchased from ANASPEC), B16- M20 
( FRRK AFLH WYTG EAMD EMEF TEAESNM) (Purity: % 
peak area by HPLC ≥99%, synthesis by ChinaPeptides), 
B16- M30( PSKP SFQE FVDW ENVS PELN STDQPFL) 
(Purity: % peak area by HPLC ≥99%, synthesis by China-
Peptides) were used CT26- M13( AGTQ CEYW ASRA LDSE 
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HSIG SMIQLPQ) (Purity: % peak area by HPLC ≥90%, 
synthesis by ChinaPeptides), CT26- M55( EGDP CLRS 
SDCI DEFC CARH FWTKICK) (Purity: % peak area by 
HPLC ≥90%, synthesis by ChinaPeptides).21
Preparation of a single-cell suspension of spleen and flow 
cytometry analysis
Mice were sacrificed after the cryo- thermal therapy, 
and the spleens were collected (n=4 per group at each 
time point). A single- cell suspension of splenocytes 
was prepared using GentleMACS dissociator (Miltenyi 
Biotec, Bergisch Gladbach, Germany), and then treated 
with erythrocyte- lysing reagent containing 0.15 M 
NH4Cl, 1.0 M KHCO3 and 0.1 mM Na2EDTA (ethylene-
diaminetetraacetic acid) to remove the red blood cells. 
The cells were dispersed using 70 µm mesh screens and 
used for analysis of antigen- specific T- cells and T- cell 
expansion.
For cell surface staining, the cells were stained with 
fluorescence conjugated antibodies which could bind 
specific surface marker at 4 °C for 30 min. For intercel-
lular cytokine staining, cells were cultured with with 
Brefeldin A (BFA), surface staining, fixed, permeabilized 
and incubated with anti- interferon-γ (IFN-γ) monoclonal 
antibody (mAb). Foxp3 staining were conducted by True- 
Nuclea Transcription Factor Buffer Set (Biolegend). 
Data were acquired using BD FACS Aria II cytometer 
(BD Biosciences) and analyzed using FlowJo V.10 soft-
ware (FlowJo LLC, Ashland, Oregon, USA). Fixation 
Buffer, Intracellular Staining Permeabilization Wash 
Buffer and BFA were purchased from Biolegend (San 
Diego, CA). Fluorochrome- conjugated mAb: CD3- 
FITC (clone 145–2 C11), CD3- PerCP/Cy5.5 (clone 
145–2 C11), CD4- PE/Cy7 (clone GK1.5), CD8- APC/Cy7 
(clone 53–6.7), IFN-γ-PE (clone XMG1.2), CD25- FITC 
(clone 3C7), CD69- Brilliant Violet 421 (clone H1.2F3), 
perforin- PE (clone S16009A), granzyme B- APC (clone 
QA16A02), PD-1- PE/Cy7 (clone RMP1-30), Foxp3- PE 
(clone MF-14) were all purchased from Biolegend. 
Zombie Violet Fixable Viability Kit was purchased from 
Biolegend to assess live vs dead status of cells.
Generation of effector T-cells from spleen
Single splenocytes were resuspended at 2×106 cells per mL 
in RPMI 1640 medium (Hyclone, USA) supplemented 
with 15% FBS, 100 units/mL penicillin and 100 µg/mL 
streptomycin and cultured in 24 well plates. For antibody 
stimulation, the plates were precoated with 10 µg/mL 
anti- CD3 mAb (Biolegend, clone 2c11) at 4℃ overnight. 
For peptides stimulation, 10 µg/mL peptides were added 
in culture medium. After 2 days of stimulation, the T- cells 
were harvested and expanded in RPMI 1640 medium 
supplemented with 15% FBS, 100 units/mL penicillin, 
100 µg/mL streptomycin, 60 IU/mL recombinant human 
interleukin 2 (rhIL-2) and 50 µM beta- mercaptoethanol 
and cultured in six well plates for three additional days. 
T- cells were then harvested, washed twice in PBS, counted 
and used for adoptive T- cell therapy and analysis of 
antigen- specific T- cells.
Analysis of antigen-specific T-cells
Splenocytes or expanded T- cells were cocultured with 
1 µg/mL peptide, respectively, for 12 hours, and BFA was 
added in the last 4 hours to enhance intracellular cytokine 
staining signals. Intracellular analysis of IFN-γ production 
was measured by flow cytometry.
Depletion of CD4+ and CD8+ T-cell subsets in vivo
For T- cell- depleting experiments, the treated mice (n=4 
mice per group) were depleted with anti- CD4 or anti- CD8 
mAb (Sungene Biotech), respectively (mice were injected 
i.p. with 300 µg mAb against CD4 or CD8, on day 1, 4, 7, 
10 and 13 after cryo- thermal therapy). The effect of mAb 
depletion was confirmed in vivo.
Adoptive T-cell therapy
Naïve mice were fused with 1×105 B16F10 cells via tail vein 
injection. Three days later, 4×107 expanded T- cells from 
donors of naïve, untreated, cryo- thermal therapy and 
RFA were adopted to these mice via tail vein injection. 
After T- cell adoption, 90 000 IU IL-2 was given to all mice 
three times per day for three continuous days. On day 
14 after adoptive T- cells therapy, mice were sacrificed to 
count the number of lung tumor nodules.
Western blot analysis
Tumors were harvested at 0, 3, 6, 12 and 24 hours after 
treatments. Tumor tissue was wrapped with Nylon filter 
paper with a pore size of 15 µm and centrifuged at 
2500 rpm in a 15 mL centrifuge tube for 20 min. Tumor 
interstitial fluid was collected. 50 µg of total proteins were 
separated onto a 4%–20% gradient Tris- Glycine precast 
gel and transferred to a PVDF membrane. Blot was probed 
with anti- TRP2 (Abcam). Each shown Western blot was a 
representative from three separate experiments.
Statistical analysis
All data are presented as mean±SD. Significance was 
determined using a two- sided Student’s t- test, a one- way 
analysis of variance (ANOVA) with Holm- Sidak correc-
tion for multiple comparisons, or a two- way ANOVA 
with Holm- Sidak correction for multiple comparisons. 
A Mann- Whitney rank sum test was used if data did not 
follow a normal distribution. Significant differences in 
survival were determined using a log- rank (Mantel- Cox) 
test. GraphPad Prism V.7.0 (La Jolla, California, USA) was 
used for all statistical analysis.
RESULTS
Cryo-thermal therapy-induced strong and long-lasting 
immune-mediated rejection of contralateral tumor growth and 
lung metastasis
The antitumor therapeutic efficacy of cryo- thermal 
therapy was verified in several independent experiments 
using both 4T1 murine mammary cancer and B16F10 
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murine melanoma models.15–17 Here, we performed new 
experiments to demonstrate the long- term survival benefit 
of cryo- thermal therapy in the B16F10 murine melanoma 
model. RFA (60 °C for 15 min) and cryo- thermal therapy 
(prefreezing at −20°C for 5 mi, followed by RF heating 
at 50 °C for 10 min) were performed on primary tumors 
12 days after tumor inoculation. As shown in figure 1A, 
during the observation period of over 180 days, all 12 mice 
in the tumor- bearing control group died, but 10 of 12 
(~83.3%) mice in the cryo- thermal therapy group and 9 of 
12 (75%) mice in the RFA group survived. To determine 
whether cryo- thermal therapy or RFA- induced strong 
systematic or long- term antitumor immunity, contralat-
eral tumors were used to estimate the strength of the 
immune response after treatments. One week after local 
tumor inoculation with 5×105 B16F10 cells, 1×105 B16F10 
cells were inoculated into the contralateral flank. All mice 
receiving RFA therapy could not suppress the contralat-
eral tumor growth and died in 60 days, while three of four 
(75%) mice treated with cryo- thermal therapy rejected 
the contralateral tumor growth (figure 1B). This result 
suggested that a stronger systematic antitumor immune 
response was induced by cryo- thermal therapy to reject 
contralateral tumor growth. To investigate whether long- 
term antitumor immunity was induced after treatments, 
45 days later, both naïve and survived mice were intra-
venously infused with 1×105 B16F10 melanoma cells and 
lung metastatic nodules were enumerated on day 78 after 
tumor inoculation. All control mice developed tumor 
nodules in the lungs. Substantial number of lung tumor 
nodules were observed in the RFA group. In contrast, no 
lung metastasis was found in long- term survivors treated 
Figure 1 Cryo- thermal therapy- induced systematic and long- term antitumor immunity. (A) Kaplan- Meier survival curve. Cryo- 
thermal therapy and RFA improved long- term survival in comparison with untreated group. Approximately 5×105 B16F10 cells 
were injected subcutaneously into the right flank of each mouse. Twelve days later, mice were treated with RFA or cryo- thermal 
therapy, and untreated mice were as control. Kaplan- Meier survival curve was compared using log- rank tests. ***P<0.001, 
****p<0.0001. n=12 for each group. (B) Distant tumor growth of mice treated with cryo- thermal therapy or RFA. Seven days after 
5×105 B16F10 cells implanted subcutaneously into the right flank, 1×105 B16F10 cells were injected subcutaneously into the 
left flank. Another 5 days later, mice were treated with RFA or cryo- thermal therapy, and untreated mice were set as control. 
Kaplan- Meier survival curve was compared using log- rank tests. *P<0.05, **p<0.01. n=4 for each group. (C) B16F10 rechallenge 
on mice treated with cryo- thermal therapy or RFA. Upper: schematic of experimental design. Mid: photographic images of lungs 
from cryo- thermal or RFA- treated and untreated mice, respectively. Lower: quantitative statistics of tumor nodules in lung. All 
data were shown as mean±SD. n=6 per group. **P< 0.01, ****p<0.0001. Data for graphs were calculated using one- way ANOVA. 
ANOVA, analysis of variance; RFA, radiofrequency ablation.
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with cryo- thermal therapy (figure 1C). The results indi-
cated that local cryo- thermal therapy generated a strong 
systematic antitumor immune response and long- term 
antitumor immunity that protected against tumor rechal-
lenge and inhibited the lung metastases.
Tumor antigen-specific CD8+ and CD4+ T-cells were generated 
after cryo-thermal therapy
Long- term antitumor responses against tumor- associated 
antigens are thought to be mainly mediated by T- cells.29 
The recognition of tumor cells by T- cells is dependent on 
the interaction of TCRs and MHC- peptide complexes.29 
Our previous studies demonstrated that the percentage 
of CD4+ and CD8+ T- cells was significantly increased 
after cryo- thermal therapy.17–19 However, whether tumor 
antigen- specific CD4+ and CD8+ T- cells were induced by 
cryo- thermal therapy had not been addressed. MHC- I- 
restricted peptides of TRP2, tyrosinase and gp100, three 
known antigens of B16F10 melanoma21 were used to esti-
mate the frequency of antigen- specific CD8+ T- cells, and 
MHC- II- restricted peptides of B16- M30 and B16- M20, two 
neoantigens of B16F10 melanoma21 were used to estimate 
the frequency of antigen- specific CD4+ T- cells. On day 14 
after treatment, splenocytes derived from mice treated 
with RFA or cryo- thermal therapy were coincubated with 
these peptides for 24 hours. The frequency of IFN-γ-pro-
ducing CD4+ and CD8+ T- cells was detected by flow 
cytometry (online supplemental figure S1). Naïve mice 
and tumor- bearing mice were used as control groups. 
Mice treated with RFA or cryo- thermal therapy had strong 
TRP2- specific and tyrosinase peptide- specific CD8+ T- cell 
responses compared with naïve and untreated mice, while 
no significant difference was found among the four groups 
when splenocytes were coincubated with gp100 peptides 
(figure 2A, online supplemental figure S2A). These data 
showed that both cryo- thermal therapy and RFA induced 
tumor antigen- specific CD8+ T- cell responses. For MHC- 
II- restricted neoantigen peptides, there was no evident 
B16- M30 specific CD4+ T- cell response induced in all 
groups, while the percentage of B16- M20- specific CD4+ 
T- cells was significantly increased after cryo- thermal 
therapy compared with that in the other three groups 
(figure 2B, online supplemental figure S2B). Meanwhile, 
we also analyzed antigen specific T- cell in CT26 model as 
shown in online supplemental figure S3, and we found 
that the level of specific CD8+ T- cells and CD4+ T- cells 
induced by cryo- thermal therapy were higher than RFA, 
which was very similar in B16F10 model. These data 
indicated that the antigen- specific CD8+ T- cell response 
was induced after cryo- thermal therapy and RFA, but 
a stronger antigen- specific CD4+ T- cell response was a 
distinct characteristic after cryo- thermal therapy.
Tumor antigen-specific T-cells generated by cryo-thermal 
therapy were more effective against tumor rechallenge than 
RFA
Thus far, our previously published and current results 
documented that cryotherapy can treat well- established 
tumor and generated systemic T- cell- based antitumor 
immunity. To further demonstrated the antitumor efficacy 
of T- cells induced by cryo- thermal therapy, we performed 
adoptive T- cell therapy experiments. To obtain enough 
effector T- cells, splenocytes from naïve mice, untreated 
and treated mice were first stimulated with anti- CD3 mAb 
for 2 days and then expanded with IL-2 for another 3 days. 
The majority of naïve T- cells differentiated into effective 
memory T- cells after stimulation with anti- CD3 mAb.30 
The percentages of antigen- specific CD4+ and CD8+ T- cells 
after expansion were identified via coculturing MHC- I- 
restricted and MHC- II- restricted peptides. As shown in 
figure 3B,C, the basic levels of antigen- specific T- cells 
cocultured with MHC- I- restricted and MHC- II- restricted 
Figure 2 Frequency of IFN-γ+ cells in CD8+ and CD4+T- cells. On day 14 after RFA or cryo- thermal therapy, splenocytes were 
obtained from naïve mice, untreated mice and treated mice. (A) Each 1×105 splenocytes were coincubated with 10 µg/mL 
TRP2, tyrosinase, gp100, ova (negative control), 100 ng/mL αCD3 (positive control) and medium (blank control), respectively, 
to measure IFN-γ+ CD8+ T- cells. (B) Each 1×105 splenocytes were coincubated with 10 µg/mL B16- M20, B16- M30, 100 ng/mL 
αCD3 (positive control) and medium (blank control), respectively, to measure IFN-γ+ CD4+ T- cells. Mean percentages of IFN-γ+ 
CD8+ T- cells (A) and IFN-γ+ CD4+ T- cells (B) in each group were shown (data for bar graphs were calculated using two- way 
ANOVA, *p<0.05), n=4 for each group. ANOVA, analysis of variance; IFN-γ, interferon-γ; RFA, radiofrequency ablation.
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peptides were increased in all groups after expansion 
compared with that before expansion, indicating the 
maturation of T- cells during expansion. Splenocytes from 
mice receiving RFA and cryo- thermal therapy after stim-
ulation yielded many more antigen- specific CD8+ T- cells 
than those from untreated mice. Moreover, the frequency 
of antigen- specific CD8+ T- cells expanded from mice 
receiving cryo- thermal therapy was much higher than 
that from mice receiving RFA (figure 3B). The results 
indicated that cryo- thermal therapy endowed antigen- 
specific CD8+ T- cells with more differential ability than 
did RFA. In addition, the frequency of B16- M20- specific 
CD4+ T- cells in spleen from mice receiving RFA and cryo- 
thermal therapy was increased and was higher than that 
from the untreated mice (figure 3C and online supple-
mental figure S4A). However, the frequency of B16- 
M30- specific CD4+ T- cells in spleen from mice receiving 
cryo- thermal therapy was much higher than that from 
mice receiving RFA and untreated mice (figure 3C). The 
data revealed that neoantigen- specific CD4+ T- cells were 
weakly activated after RFA but were strongly activated 
after cryo- thermal therapy. Then, 4×107 expanded T- cells 
were adoptively transferred into mice received 1×105 
B16F10 tumor cells via tail vein injection 3 days before 
Figure 3 Adoptive T- cells therapy using expanded T- cells from mice treated with cryo- thermal therapy and RFA. (A) Schematic 
of experimental design. (B, C) Frequency of IFN-γ+ cells in CD8+ T- cells and CD4+ T- cells stimulated with αCD3 and then 
expanded with IL-2. Mean percentages of IFN-γ+ CD8+ T- cells (B) and IFN-γ+ CD4+ T- cells (C) in each group were shown (data 
for bar graphs were calculated using two- way ANOVA, *p<0.05), n=4 for each group. (D) Tumor nodules in lung after adoptive 
T- cells therapy. Left: photographic images of lungs from mice receiving expanded T- cells from naïve mice, untreated, cryo- 
thermal- treated and RFA- treated mice, respectively. Right: quantitative statistics of tumor nodules in lung. All data were shown 
as mean±SD n=6 per group. ***P< 0.001, ****p<0.0001. Data for graphs were calculated using one- way ANOVA. ANOVA, 
analysis of variance; IFN-γ, interferon-γ; RFA, radiofrequency ablation.
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T- cell transfer. After T- cell transfer, 90 000 UI rhIL-2 was 
given three times per day for three continuous days. On 
day 14 after adoptive T- cell therapy, mice were sacrificed, 
and the number of lung tumor nodules was enumerated. 
The number of lung tumor nodules in mice receiving 
expanded T- cells from mice treated with RFA and cryo- 
thermal therapy was significantly less than that in naïve 
mice, clearly demonstrated that the antitumor immunity 
was induced by T- cells after RFA and cryo- thermal therapy 
(figure 3D). However, the number of lung tumor nodules 
in mice receiving expanded T- cells from mice treated with 
RFA was not significantly different from that in untreated 
mice, while the number of lung tumor nodules in mice 
receiving expanded T- cells from mice treated with cryo- 
thermal therapy was fewer than that in RFA- treated and 
untreated mice (figure 3D and online supplemental 
figure S4B). In general, mice receiving expanded T- cells 
from mice treated with cryo- thermal therapy developed 
rare lung tumor nodules, which represented a stronger 
antitumor immunity induced by T- cells after cryo- thermal 
therapy. The results showed that the antigen- specific 
CD4+ and CD8+ T- cells induced by cryo- thermal therapy 
were much more activated than those induced by RFA, 
and these activated cells are robust effector cells to exert 
a stronger antitumor immunity to inhibit metastasis.
Neoantigen-specific CD4+ T-cells were the major contributors 
in the cryo-thermal therapy-induced strong antitumor 
immune response
Since the antigen- specific CD4+ and CD8+ T- cell responses 
induced by cryo- thermal therapy after expansion were 
stronger than those induced by RFA, we further exam-
ined the independent role of CD4+ and CD8+ T- cells in 
cryo- thermal therapy- induced antitumor immunity in 
adoptive transfer experiments with CD4 or CD8 effector 
T- cells. Mice were injected with 300 µg anti- CD4 or anti- 
CD8 mAb on days 1, 4, 7, 10 and 13 after cryo- thermal 
therapy, and on day 14, mice were sacrificed to obtain sple-
nocytes as the source of CD4+ or CD8+ T- cells (figure 4A). 
The depletion of CD4+ or CD8+ T- cells was verified by flow 
cytometry (online supplemental figure S5A‒C). Adoptive 
T- cell therapy was performed as described in figure 3A. 
As shown in figure 4B,C, the number of lung tumor 
nodules in mice receiving expanded T- cells from mice 
treated with cryo- thermal therapy was lower than that in 
untreated mice.
In most animal models, it has been well established 
that both CD4 and CD8 are important to the efficacy 
of adoptive T- cell therapy.31 32 Interestingly, the number 
of lung tumor nodules in mice receiving adoptive CD4+ 
Figure 4 Adoptive T- cells therapy using expanded CD8+ or CD4+ T- cells obtained through depletion in vivo with mAb, 
respectively. (A) Schematic of experimental design. (B) Tumor nodules in lung after adoptive T- cells therapy. Left: photographic 
images of lungs from mice receiving expanded T- cells from untreated, cryo- thermal- treated mice, CD4+ T- cells from cryo- 
thermal therapy (cryo- thermal therapy+αCD8) and CD8+ T- cells from cryo- thermal therapy (cryo- thermal therapy+αCD4), 
respectively. Right: quantitative statistics of tumor nodules in lung. All data were shown as mean±SD. n=6 per group. 
***P<0.001, ****p<0.0001. Data for graphs were calculated using one- way ANOVA. ANOVA, analysis of variance; IL2, interleukin 
2; mAb, monoclonal antibody.
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T- cell therapy (cryo- thermal therapy+αCD8) was only 
slightly more than that in mice receiving normal adop-
tive T- cell therapy (cryo- thermal therapy). However, the 
number of lung tumor nodules in mice receiving adop-
tive CD8+ T- cell therapy (cryo- thermal therapy+αCD4) 
was much more than that in mice receiving adoptive 
CD4+ T- cell therapy and normal adoptive T- cell therapy 
(figure 4B,C). The results demonstrated that the strong 
antitumor immune response induced by cryo- thermal 
therapy was mainly mediated by CD4+ T- cells, which had 
a powerful antitumor ability to reject tumor challenge.
However, T- cells stimulated with anti- CD3 mAb are 
activated and expand, leading to a case in which many 
of T- cells are not antigen- specific T- cells.33 To deter-
mine whether antigen- specific CD4+ T- cells played a 
critical role in cryo- thermal therapy- induced antitumor 
immunity, MHC- II- restricted peptides were used instead 
of anti- CD3 mAb to stimulate T- cells to yield a mono-
clonal or oligoclonal response. After stimulation with 
MHC- II- restricted peptides (B16- M30 and B16- M20) 
for 2 days, splenocytes were then expanded by IL-2 for 
another 3 days (figure 5A). Adoptive T- cell therapy was 
performed, and the procedure was the same as described 
in figure 3A. The number of lung tumor nodules in mice 
receiving αCD3- stimulated T- cells from cryo- thermal 
therapy- treated mice was fewer than that in RFA- treated 
mice (figure 5B,C), which was consistent with the above 
results that the frequency of antigen- specific CD4+ and 
CD8+ T- cells expanded from mice receiving cryo- thermal 
therapy was much higher than that from mice receiving 
RFA (as shown in figure 3B,C). Moreover, the number of 
lung tumor nodules in mice receiving neoantigen peptide- 
stimulated CD4+ T- cells from cryo- thermal therapy- 
treated mice was also fewer than that in RFA- treated mice 
(figure 5B,C). This result was in agreement with much 
higher frequency of neoantigen- specific CD4+ T- cells after 
expansion from cryo- thermal therapy- treated mice than 
that from RFA- treated mice (figure 3C). The number of 
lung tumor nodules in mice receiving expanded adoptive 
peptide- stimulated CD4+ T- cell therapy was not signifi-
cantly different from that in mice receiving adoptive 
αCD3- stimulated T- cell (containing both CD4+ and CD8+ 
Figure 5 Adoptive T- cells therapy using αCD3- stimulated or MHC- II- restricted peptides- stimulated CD4+ T- cells. (A) 
Schematic of experimental design. (B, C) Tumor nodules in lung after adoptive T- cells therapy. (B) Photographic images of 
lungs photographic images of lungs from mice receiving αCD3- or MHC II restricted peptides- stimulated T- cells from cryo- 
thermal therapy or RFA. (C) Quantitative statistics of tumor nodules in lung. All data were shown as mean±SD. n=6 per group. 
NS, *p≥0.05. Data for graphs were calculated using two- sided Student’s t- test. IL2, interleukin 2; NS, not significant; RFA, 
radiofrequency ablation.
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T- cells) therapy, which could generate strong immune 
responses that protected against tumor rechallenge and 
lung metastases (figure 5B,C). These data demonstrated 
that after cryo- thermal therapy, neoantigen- specific CD4+ 
T- cells were likely the major contributor to the antitumor 
immune response in cryo- thermal therapy.
DISCUSSION
In this study, we documented that local cryo- thermal 
therapy generated a stronger systematic antitumor 
immune response than RFA and a long- lasting anti-
tumor immunity that protected against tumor rechal-
lenge. At the same time, a systemic antigen- specific 
T- cell immune response induced via local cryo- thermal 
therapy was revealed. Although the survival rate between 
RFA and cryo- thermal therapy was not statistically signif-
icant, the long- term immunity against tumor challenge 
elicited by two treatments was different. In vitro studies 
showed that the antigen- specific CD8+ T- cell response was 
induced by both cryo- thermal therapy and RFA, but the 
strong neoantigen- specific CD4+ T- cell response was only 
induced by cryo- thermal therapy. Moreover, we demon-
strated that the cryo- thermal therapy- induced strong anti-
tumor immune response was mainly mediated by CD4+ 
T- cells, particularly neoantigen- specific CD4+ T- cells, 
which are the major contributors to the cryo- thermal 
therapy- induced antitumor immune response.
To induce a T- cell- mediated antitumor immune 
response for the effective killing of tumor cells, a series of 
stepwise events must be initiated.34 Initially, antigens and 
factors that elicit the innate immune response are created 
by tumor cell necrosis.34 Our previous studies showed 
that coagulative necrosis was the major mode of death 
in RFA, while most tumor cells underwent immunogenic 
necrosis after cryo- thermal therapy, which resulted in the 
release of a larger amount of damage- associated molec-
ular patterns (DAMPs), such as HSP70 and HMGB1, to 
peripheral tumor tissues and peripheral blood after cryo- 
thermal therapy compared with RFA.16 At the same time, 
the release of the tumor antigen TRP2 the tumor stroma 
was significantly increased after cryo- thermal therapy 
compared with RFA (online supplemental figure S6). 
Next, antigens are internalized, processed and presented 
on MHC molecules by host APCs. The DAMPs released by 
dying tumor cells promote the activation and maturation 
of APCs, enhancing their antigen presentation ability.35 
The flood of DAMPs released after cryo- thermal therapy 
elicits the activation of innate immunity, promoting DC 
maturation and M1 macrophage polarization.16 18 19 36 
Finally, mature APCs present the peptide derived from 
captured antigens on MHC- I and MHC- II molecules to 
CD8+ and CD4+ T- cells, resulting in activation of effector/
memory CD8+ and CD4+ T- cell responses against the 
tumor- specific antigens (TSAs).37 Our previous studies 
revealed that cryo- thermal therapy induced M1 macro-
phage polarization and modulated DC maturation, 
resulting in CD4+ T- cell differentiation into Th1 and 
cytotoxic T- cell subsets and the generation of cytotoxic 
CD8+ T- cells.17 19 In particular, the synergistic effect of 
thermal and mechanical stresses induced by cryo- thermal 
therapy led to vastly increased tumor cell break- down; 
in addition, B16F10 melanoma has a high mutation 
burden,21 and more neoantigens leaking out of broken 
tumor cells after cryo- thermal therapy were internalized, 
processed and presented on MHC- II molecules by APCs, 
which resulted in a stronger neoantigen- specific CD4+ 
T- cell response triggered by cryo- thermal therapy than by 
RFA. However, in this study, we have not examined the 
release of neoantigens due to the lack of antibodies of 
neoantigen.
CD4+ T- cells are the orchestrators of the antitumor 
immune response and played a central role in anti-
tumor efficacy.25 38 Recent studies have shown that CD4+ 
T- cells can clear tumors completely independently of 
CD8+ T- cells.39 Our previous studies identified that 
cryo- thermal therapy markedly promoted the differen-
tiation of CD4+ T- cells, which contributed to the induc-
tion of a durable- specific memory immune response.17 19 
IFN-γ+CD4+ T- cells are one of the CD4+ T- cell subsets and 
are known as Th1 cells. IFN-γ secreted by CD4+ T- cells 
upregulates the expression of MHC- II on tumor cells; 
thus, CD4+ T- cells are capable of recognizing and killing 
MHC- II- expressing target cells directly in an MHC- II- CD4 
restricted way.40 IFN-γ can also directly induce permanent 
growth arrest in tumors synergistically with TNF-α.41 CD4+ 
T- cells can help prime CD8+ T- cells and maintain the 
function and promote the proliferation of CD8+ T- cells.42 
Moreover, CD4+ T- cells can promote the recruitment and 
infiltration of other immune cells, such as CD8+ T- cells, 
macrophages, granulocytes, eosinophils and NK cells.43 44 
Therefore, recent findings highlight new opportunities 
for CD4+ T- cells in cancer immunotherapy.45
Since there are several advantages of tumor specific 
CD4+ T- cells, we explored immunotherapeutic options for 
metastatic tumors. After cryo- thermal therapy, more acti-
vated and cytotoxic CD4+ and CD8+ T- cells were induced 
(online supplemental figure S7). Moreover, the frequen-
cies of antigen- specific CD8+ T- cells and CD4+ T- cells were 
increased, especially the frequency of neoantigen- specific 
CD4+ T- cells. Adoptive transfer of CD4+ T- cells stimulated 
with neoantigen peptide could effectively mediate tumor 
regression and protect mice against tumor rechallenge. 
Therefore, we suggest that adoptive cell transfer with 
tumor- specific T- cells induced by cryo- thermal therapy 
is a promising therapeutic strategy. In adoptive T- cell 
therapy, tumor- infiltrating or circulating autologous 
lymphocytes can be isolated, selected in vitro, expanded 
and then reinfused into the patient.46 In general, one 
challenge for adoptive T- cell therapy is enough to 
obtain enough tumor- specific T- cells. Adoptive T- cell 
therapy derived from tumor- infiltrating lymphocytes 
has been almost exclusively used to treat patients with 
malignant melanoma due to the difficulty in isolating 
and expanding pre- existing tumor- reactive T- cells from 
patients with other tumor types.47 However, in this study, 
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tumor- specific T- cells were markedly activated by cryo- 
thermal therapy. Moreover, many other challenges are 
involved in adoptive T- cell therapy, such as lack of unique 
tTSAs, inefficient homing of T- cells to tumor sites and the 
immunosuppressive microenvironment of solid tumors.48 
However, cryo- thermal therapy offered abundant anti-
gens by inducing immunogenic tumor cell death, 
reversed the immunosuppressive microenvironment by 
promoting the differentiation of MDSCs, maturation of 
DCs and polarization of M1 macrophages and gener-
ated abundant cytotoxic T- cells.15–19 36 The CD4+ T- cell 
response is diverse, including Th1, Th2, Th17, Tfh cells 
as well as CTLs and Tregs. In cancer, Tregs are predomi-
nantly immune suppressive.49 In the presence of adoptive 
immunosuppressive T- cell subsets, the antitumor activity 
of adoptive T- cells is impaired or inhibited, which affects 
the efficacy of adoptive T- cell therapy.45 Moreover, cryo- 
thermal therapy generated Th1- biased and CTL- biased 
CD4+ T- cells and cytotoxic CD8+ T- cells.17 Thus, this study 
provides a method for the production of activated tumor- 
specific T- cells via cryo- thermal therapy. At present, we did 
not have data about neoantigen- specific T- cell responses 
induced by cryo- thermal therapy in human tumors, but 
we will study the issue in near future.
CONCLUSIONS
In summary, cryo- thermal therapy induced strong long- 
lasting antitumor immunity through the activation of 
antigen- specific T- cells, especially neoantigen- specific 
CD4+ T- cells, to protect against tumor rechallenge and 
lung metastases. Thus, cryo- thermal therapy not only 
represents a novel local tumor therapy that leads to 
strong systemic antitumor immunity but also provides a 
method to obtain sufficient antigen- specific T- cells for 
tumor treatment.
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